- The Open Cancer Journal 2008
Constab's Scientific VP, Dr. Vladimir Pak, published an article titled "The Use of AFP-Complexes to Induce Apoptosis in Cancer Cells.
- ICDDD 2008
Constab presented a poster at the 1st International Conference on Drug Design and Discovery that was held in Dubai, UAE from February 4-7, 2008. This conference presented cutting edge advances in various disciplines where scientific experts exhibited their findings.
Constab Pharmaceutical Inc. is a Canadian biotech company that has developed a novel targeted-delivery platform involving alpha-fetoprotein (AFP) as a carrier for anticancer agents. Since most cancers express AFP receptors (AFPR), this technology could be used to treat the majority of cancers.
- OncoShuttle™: A Targeted Drug-Delivery Platform
Constab Pharmaceutical has developed a unique technology named OncoShuttle™ allowing the delivery of anti-cancer drugs directly to cancer cells. A major advantage of this technology is that AFPR are absent or present in insufficient amounts on the surface of normal cells so the anticancer drugs would be avoiding healthy tissues. This would potentially eliminate or reduce side effects for the patients and improve their quality of life.
- Aimpila™: Constab drug candidate
Constab has developed a drug candidate called Aimpila™ which combines its proprietary drug-delivery platform OncoShuttle™ to a powerful apoptosis inducer. Aimpila™ has been tested in animal models and in human with various solid tumours. The latest study results in colorectal cancer will be presented at the ASCO meeting in Chicago on June 3 in the morning session.